Immorta Bio Readies AI-Designed Senolytic Peptide for Human Trials

Accumulation of senescent cells, often termed zombie cells, is linked to systemic inflammation and tissue degradation across a spectrum of conditions including cardiovascular disease, neurodegeneration, and cancer. While existing small-molecule senolytics have shown promise in laboratory models, they frequently struggle with off-target toxicity and a lack of durable immune memory. Immorta Bio’s approach shifts the paradigm by leveraging a synthetic peptide to retrain the immune system to recognize and eliminate these cells naturally.

Advancing Senolytic Immunotherapy

Developed through computational screening, the SenoMune™-0257 candidate stimulates cytotoxic T cells to target senescent tissue while leaving healthy cells intact. According to CEO Boris Reznik, the transition from complex cellular therapies to a scalable, off-the-shelf peptide represents a major leap in manufacturing efficiency and accessibility. Thomas Ichim, the company’s Chief Scientific Officer, noted that the firm has established a discovery engine capable of generating further peptide-based immunotherapies by identifying new targets associated with cellular aging. With preclinical milestones met, the company is now focused on human evaluation, positioning its platform as a potential cornerstone for treating age-related pathologies as a unified medical category.